You are here

Preclinical development of novel small molecule malaria drugs that overcome drug

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI094959-03A1
Agency Tracking Number: R42AI094959
Amount: $2,983,056.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-124
Timeline
Solicitation Year: 2010
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-04-15
Award End Date (Contract End Date): 2019-03-31
Small Business Information
2828 SW CORBETT AVE STE 114
Portland, OR 97201-4811
United States
DUNS: 623389009
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID PEYTON
 (503) 725-3875
 peytond@pdx.edu
Business Contact
 LYNNOR STEVENSON
Phone: (503) 771-0173
Email: lynnor.stevenson@verizon.net
Research Institution
 PORTLAND STATE UNIVERSITY
 
BOX 751
PORTLAND, OR 97207-0751
United States

 Nonprofit college or university
Abstract

DESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been selected from this innovative class of potent antimalarials designed to overcome drug resistance The candidate will be advanced through the ultimate stages of preclinical testing Thus pharmacokinetics pharmacodynamics pharmacology and toxicity evaluations will be performed in both rats and monkeys The overall goal will be completion of preclinical studies leading to approval of an Investigative New Drug IND application for the drug to be used in a Phase human clinical trial PUBLIC HEALTH RELEVANCE Malaria is a disease that infects about half a billion people annually and kills nearly one million most of whom are children or pregnant women The impact of malaria remains partly because the parasite that causes malaria has evolved into strains that are resistant to the best current drugs for treating the disease This project completes preclinical evaluation of a novel drug candidate that was designed to circumvent malariaandapos s drug resistance paving the way toward approval for human clinical trials The drug candidate has shown very promising results in early studies and also has been designed to be inexpensive as well as safe for all target groups including pregnant women and children

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government